DM RWE appoints Dr. Alexey Gurochkin as its Medical Director
Dr. Alexey Gurochkin, who previously headed medical departments at Eli Lilly, Boehringer Ingelheim and Novartis Pharma, was appointed Medical Director of DM RWE, a technology company in clinical research. The appointment is connected with the introduction of a new direction for the company, Real-World Evidence solutions for clinical research.
A graduate of the Lomonosov Moscow Medical Academy, with a PhD in Clinical Pharmacology and Cardiology, Alexey Gurochkin started his career in the pharmaceutical industry back in 2002. He has more than 9 years of experience working for Novartis Pharma, as well as extensive experience in the American pharmaceutical company, Eli Lilly and the German company, Boehringer Ingelheim.
At DM RWE, Alexey Gurochkin will be responsible for coordinating work and participating in communication with pharmaceutical companies and medical organizations. Another priority task is to develop algorithms for solving research tasks together with the machine learning team, and manage project progress from a medical point of view.
"Alexey has extensive experience in healthcare organizations," says Dmitry Sharov, founder of DM RWE. “He has been successfully involved in the creation and development of large-scale medical projects. I am sure that he will cope with the most important tasks that we set for ourselves today, including the projects with big data in clinical trials."